First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

NCT06730373 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Gastric Cancer
Metastatic Gastric Cancer
Unresectable Gastric Carcinoma

Interventions

DRUG: Disitamab Vedotin
DRUG: Sintilimab
DRUG: S-1
DRUG: Trastuzumab
DRUG: Oxaliplatin
DRUG: Capecitabine
DRUG: 5-FU
DRUG: Cisplatin

Sponsor

Qilu Hospital of Shandong University